凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06821 凯莱英

未开盘 05-02 16:08:16

66.600

+2.450

+3.82%

最高66.900	最低64.050	成交量7.43万
今开64.050	昨收64.150	日振幅4.44%
总市值246.07亿	流通市值18.35亿	总股本3.69亿
成交额491.94万	换手率0.27%	流通股本2,755万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06821","market":"HK","secType":"STK","nameCN":"凯莱英","latestPrice":66.6,"timestamp":1714637296034,"preClose":64.15,"halted":0,"volume":74280,"delay":0,"floatShares":27553260,"shares":369471533,"eps":6.793763,"marketStatus":"未开盘","marketStatusCode":0,"change":2.45,"latestTime":"05-02 16:08:16","open":64.05,"high":66.9,"low":64.05,"amount":4919379,"amplitude":0.044427,"askPrice":66.6,"askSize":200,"bidPrice":66.4,"bidSize":100,"shortable":3,"etf":0,"ttmEps":5.732654424022883,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714699800000},"adr":0,"listingDate":1639065600000,"adjPreClose":64.15,"dividendRate":0.029192,"openAndCloseTimeList":[[1714613400000,1714622400000],[1714626000000,1714636800000]],"volumeRatio":0.5085650905804543,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":82.65,"timestamp":1714460619000,"preClose":84.18,"halted":0,"volume":4022745,"delay":0,"premium":"-25.75"}},"requestUrl":"/m/hq/s/06821/","defaultTab":"news","newsList":[{"id":"2431980968","title":"凯莱英(06821.HK)合伙设立基金  拟投资创新生物制药等产业","url":"https://stock-news.laohu8.com/highlight/detail?id=2431980968","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431980968?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:06","pubTimestamp":1714439160,"startTime":"0","endTime":"0","summary":"凯莱英(06821.HK) 公布，其全资附属凯莱英生命科学技术，与信银恒泽、海尊创企业管理、海河产业基金及天津生态城订立合伙协议，共同设立基金，用于日后投资创新生物制药、合成生物等产业。根据合伙协议，基金认缴出资额总额7.54亿元人民币(下同)，当中凯莱英出资3亿元，占认缴出资额总额约39.8%。透过订立合伙协议，公司旨在加强其技术能力，支持其业务扩张计划，助推持续稳定发展，促进其产业资源与专业投资机构的专业知识和资本的良性互动。(cy/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-29 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220106150437587_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220106150437587_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346162/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431802795","title":"凯莱英(06821.HK):成立7.54亿元基金 投资创新生物制药产业","url":"https://stock-news.laohu8.com/highlight/detail?id=2431802795","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2431802795?lang=zh_cn&edition=full","pubTime":"2024-04-30 08:00","pubTimestamp":1714435245,"startTime":"0","endTime":"0","summary":"快讯正文4月30日，凯莱英发布公告称，其全资子公司凯莱英生命科学技术与信银恒泽、海尊创企业管理、海河产业基金及天津生态城订立合伙协议，共同设立基金。该基金将专注于投资创新生物制药、合成生物等产业，以推动相关领域的技术进步与产业化发展。根据合伙协议，基金认缴出资总额为人民币7.54亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300931458b642689&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300931458b642689&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431421871","title":"凯莱英(06821)拟投资3亿元与海河基金、生态城国资等设立一支生物医药创新和合成生物产业投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2431421871","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431421871?lang=zh_cn&edition=full","pubTime":"2024-04-30 07:38","pubTimestamp":1714433932,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(06821)公布，为把握国内外创新药市场的蓬勃发展机遇，通过投资专业化的生物医药创新和合成生物产业投资基金，探索通过“资产+资本+服务”的商业合作方式重点培育优质项目，持续推动公司技术能力建设与业务拓展需求，实现公司产业资源与专业投资机构资源和资本的良性互动。公司全资子公司凯莱英生命科学拟以有限合伙人身份投资3亿元人民币与海河基金、生态城国资、海尊创、信银恒泽共同投资设立一支生物医药创新和合成生物产业投资基金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1115987.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431167044","title":"抗癌概念盘中拉升，嘉应制药涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431167044","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431167044?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:45","pubTimestamp":1714355150,"startTime":"0","endTime":"0","summary":"04月29日，抗癌概念盘中拉升，截至09点45分，抗癌概念整体指数上涨1.12%，报899.170点。从个股上来看，该概念的成分股中，嘉应制药涨5.26%，金花股份、金达威、凯莱英涨幅居前。从资金上来看，截止发稿，抗癌概念主力净流入为-8242.01万，其中凯莱英受到资金热捧，主力净流入2947.42万；拉长时间线来看，该板块近20日主力资金净流入-62.20亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042909455087e84740&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042909455087e84740&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431441250","title":"凯莱英4月26日获北向资金加仓81.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431441250","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431441250?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:31","pubTimestamp":1714354265,"startTime":"0","endTime":"0","summary":"4月26日, 北向资金增持凯莱英81.62万股。截止当日收盘，深股通共持有凯莱英1488.83万股，占流通股4.35%。深股通增持金额前五个股分别为比亚迪、宁德时代、中际旭创、东方财富、迈瑞医疗。凯莱英近5个交易日上涨5.73%，深股通累计增持55.91万股；近20个交易日下跌9.42%，深股通累计减持291.97万股。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404290942378b5fa3e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404290942378b5fa3e5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430037274","title":"凯莱英：有知名机构高毅资产参与的多家机构于4月26日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2430037274","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430037274?lang=zh_cn&edition=full","pubTime":"2024-04-28 18:36","pubTimestamp":1714300571,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年4月28日凯莱英发布公告称中金公司、中欧基金、上投摩根基金、银华基金、华宝基金、招商基金、建信基金、富国基金、鹏华基金、华夏基金、嘉实基金、兴业证券、LMR、RBC Global、3W Asset、Springhill Fund、贝莱德资产、AIHC Capital、Point72、高毅资产、中信证券、中信建投证券、国盛证券、浙商证券、华泰证券、西南证券、平安证券于2024年4月26日调研我司。二季度有望延续良好态势，下半年尚需结合具体订单和排产计划情况来看。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800007262.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430034068","title":"凯莱英：公司今年一季度产能利用率情况良好，结合所执行订单项目结构改善带动整体毛利率提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2430034068","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430034068?lang=zh_cn&edition=full","pubTime":"2024-04-28 18:00","pubTimestamp":1714298458,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英04月28日在投资者关系平台上答复投资者关心的问题。公司今年一季度产能利用率情况良好，结合所执行订单项目结构改善带动整体毛利率提升。2024年度公司制定各项生产经营计划，全力拓展新业务新订单，并进一步升级管理体系、提高运营效率。同时，公司需要加快海外产能布局以进一步深化与海外客户特别是跨国制药公司的合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800006860.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430204881","title":"凯莱英获信达证券买入评级，常规业务稳健增长，海外市场持续向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2430204881","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430204881?lang=zh_cn&edition=full","pubTime":"2024-04-26 23:11","pubTimestamp":1714144310,"startTime":"0","endTime":"0","summary":"4月26日，凯莱英获信达证券买入评级，近一个月凯莱英获得12份研报关注。研报预计2024-2026年公司营业收入为63.29/78.07/98.17亿元，同比增长-19.1%/23.4%/25.7%；归母净利润分别为11.08/14.42/19.56亿元，同比增长-51.2%/30.1%/35.7%。受大订单交付完毕所致，2024Q1收入及利润增速均有所下降，剔除2023Q1大订单收入后，2024Q1营业收入同比增长15.21%，公司常规业务继续保持稳定增长态势。小分子CDMO业务持续向好，新兴业务受环境影响增速有所降低。海外市场增长强劲，积极布局海外产能以驱动后续发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042623115187b43bac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042623115187b43bac&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430224294","title":"凯莱英盘中异动 大幅拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430224294","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430224294?lang=zh_cn&edition=full","pubTime":"2024-04-26 11:09","pubTimestamp":1714100975,"startTime":"0","endTime":"0","summary":"2024年04月26日早盘11时09分，凯莱英股票出现异动，股价急速拉升5.00%。凯莱英股票所在的药品行业中，整体涨幅为0.25%。其相关个股中，海王英特龙、康龙化成、凯莱英涨幅较大，振幅较大的相关个股有三爱健康集团、开拓药业-B、康龙化成，振幅分别为13.79%、10.64%、6.70%。消息层面，截至11时09分，凯莱英股票正面舆情新闻比例14.29%。《凯莱英获国投证券买入评级，6个月目标价为85.50元》资讯为影响凯莱英的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261109367923b357&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261109367923b357&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430229217","title":"凯莱英(06821)上涨5.0%，报61.95元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430229217","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430229217?lang=zh_cn&edition=full","pubTime":"2024-04-26 11:09","pubTimestamp":1714100973,"startTime":"0","endTime":"0","summary":"4月26日，凯莱英盘中上涨5.0%，截至11:09，报61.95元/股，成交729.0万元。凯莱英医药集团是一家全球领先的CDMO公司，主要为全球新药提供从临床早期到商业化阶段的一站式研发、生产服务，包括高级中间体、原料药、制剂的研发和cGMP生产，以及临床研究服务。截至2024年一季报，凯莱英营业总收入13.64亿元、净利润2.82亿元。4月25日，公司以每股76.65-77.27人民币回购25.79万股,回购金额1981万人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/26110940424092.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430629229","title":"凯莱英(06821)股价上升5%，现价港币$61.95","url":"https://stock-news.laohu8.com/highlight/detail?id=2430629229","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430629229?lang=zh_cn&edition=full","pubTime":"2024-04-26 11:09","pubTimestamp":1714100940,"startTime":"0","endTime":"0","summary":"[上升股]凯莱英(06821) 股价在上午11:09比前收市价上升5%，现股价为港币$61.95。至目前为止，今日最高价为$61.95，而最低价为$59.1。总成交量为11.886万股，总成交金额为港币$724.045万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404262611/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2430291112","title":"凯莱英获国投证券买入评级，6个月目标价为85.50元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430291112","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430291112?lang=zh_cn&edition=full","pubTime":"2024-04-26 10:33","pubTimestamp":1714098837,"startTime":"0","endTime":"0","summary":"4月26日，凯莱英获国投证券买入评级，近一个月凯莱英获得10份研报关注。国投证券预计公司2024年-2026年的归母净利润分别为12.65亿元、14.31亿元、16.30亿元，分别同比增长-44.3%、13.2%、13.9%。预计2024年对应6个月目标价为85.50元/股。研报认为，剔除大订单同期高基数影响后，2024Q1公司收入稳健增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261045508b553190&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261045508b553190&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430298272","title":"凯莱英4月25日遭北向资金减持46.89万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430298272","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430298272?lang=zh_cn&edition=full","pubTime":"2024-04-26 09:31","pubTimestamp":1714095064,"startTime":"0","endTime":"0","summary":"4月25日，北向资金减持凯莱英46.89万股。截止当日收盘，深股通共持有凯莱英1407.21万股，占流通股4.11%。深股通减持金额前五个股分别为美的集团、汇川技术、三七互娱、科伦药业、东方财富。凯莱英近5个交易日下跌1.98%，深股通累计减持48.88万股；近20个交易日下跌16.12%，深股通累计减持384.57万股。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042609383087b14093&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042609383087b14093&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430900258","title":"图解凯莱英一季报：第一季度单季净利润同比减55.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430900258","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430900258?lang=zh_cn&edition=full","pubTime":"2024-04-26 01:53","pubTimestamp":1714067604,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英2024年一季报显示，公司主营收入14.0亿元，同比下降37.76%；归母净利润2.82亿元，同比下降55.27%；扣非净利润2.54亿元，同比下降58.88%；负债率11.26%，投资收益907.11万元，财务费用-7830.82万元，毛利率43.52%。财报数据概要请见下图:以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042602080287b0339f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042602080287b0339f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430823183","title":"《业绩》凯莱英(06821.HK)首季净利润2.82亿人民币  倒退55.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430823183","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430823183?lang=zh_cn&edition=full","pubTime":"2024-04-26 00:41","pubTimestamp":1714063260,"startTime":"0","endTime":"0","summary":"凯莱英(06821.HK) 公布3月止第一季度报告，实现营业收入14亿人民币(下同)，按年下降37.8%，主要受去年同期大订单的影响。归属股东净利润2.82亿元，倒退55.3%，每股收益76分。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-25 16:25。)过往派息公布日期派息事项派息内容2024/03/28末期业绩普通股息：人民币 1.82023/10/30第三季业绩无派息2023/08/29中期业绩无派息2023/04/28第一季业绩无派息 AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180321104350557_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180321104350557_s.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345173/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430323188","title":"凯莱英(06821.HK)共计回购689.8万A股  涉资5.78亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2430323188","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430323188?lang=zh_cn&edition=full","pubTime":"2024-04-26 00:41","pubTimestamp":1714063260,"startTime":"0","endTime":"0","summary":"凯莱英(06821.HK) 公布，4月25日止，累计回购689.83万股A股，占A股总股本2.0175%；每股作价介乎75.53-102元人民币，成交总金额5.78亿人民币。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-25 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210923151913237_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210923151913237_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345174/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430340849","title":"V观财报｜凯莱英一季度净利润降超五成","url":"https://stock-news.laohu8.com/highlight/detail?id=2430340849","media":"中新经纬","top":-1,"share":"https://www.laohu8.com/m/news/2430340849?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:46","pubTimestamp":1714041988,"startTime":"0","endTime":"0","summary":"中新经纬4月25日电 25日，凯莱英发布2024年一季报，营业收入约14亿元，比上年同期下降37.76%；归属于上市公司股东的净利润约2.82元，比上年同期下降55.27%；基本每股收益0.76元/股，比上年同期下降55.81%。来源：凯莱英2024年一季报早在3月28日，凯莱英披露2023年年度报告，公司实现营业收入约78.25亿元，同比下降23.7%；净利润约22.69亿元，同比下降31.28%；基本每股收益6.26元。股市方面，凯莱英25日收跌0.59%，总市值284亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042518475687aee5ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042518475687aee5ed&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430470112","title":"凯莱英(06821)累计回购约689.84万股A股 涉资约5.78亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430470112","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430470112?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:39","pubTimestamp":1714041560,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(06821)公布，截至 2024 年 4 月 25 日，公司累计通过回购专用证券账户以集中竞价交易方式回购公司股份数量为约689.84万股，占公司 A 股总股本的 2.0175%，最高成交价为 102.00 元/股，最低成交价为 75.53 元/股，成交总金额为约5.78亿元(不含交易费用)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1110194.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430470815","title":"凯莱英(06821)发布第一季度业绩 归母净利润2.82亿元 同比减少55.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430470815","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430470815?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:32","pubTimestamp":1714041121,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英 发布2024年第一季度业绩，该集团期内取得营业收入14亿元，同比减少37.76%;归属于母公司股东的净利润2.82亿元，同比减少55.27%;基本每股收益0.76元。报告期内，小分子业务收入12.23亿元，剔除上年同期大订单收入影响后同比增长26.58%，小分子业务毛利率47.34%，其中确认收入的小分子商业化项目30个，确认收入的小分子临床阶段项目148个，其中临床III期项目41个。新兴业务实现收入1.76亿元，受国内投融资环境持续影响，同比下降29.30%，毛利率17.30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1110166.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.asymchem.com","stockEarnings":[{"period":"1week","weight":0.1288},{"period":"1month","weight":0.1063},{"period":"3month","weight":0.1026},{"period":"6month","weight":-0.3918},{"period":"1year","weight":-0.314},{"period":"ytd","weight":-0.2681}],"compareEarnings":[{"period":"1week","weight":0.0534},{"period":"1month","weight":0.0753},{"period":"3month","weight":0.1721},{"period":"6month","weight":0.0307},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":0.068}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"凯莱英医药集团（天津）股份有限公司是一家主要从事药物定制研发生产（CDMO）的中国公司。该公司的主营业务是化学药物的工艺开发、放大和商业化，产品类别涵盖多肽、寡核苷酸、单克隆抗体、抗体偶联药物和信使RNA等。该公司还从事药物制剂解决方案、生物合成解决方案和临床解决方案的提供。","exchange":"SEHK","name":"凯莱英","nameEN":"ASYMCHEM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,06821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}